Differences between lutropin-mediated and choriogonadotropin-mediated receptor activation.
The human lutropin/choriogonadotropin receptor (hLHR) for the gonadotropic hormones human luteinizing hormone (hLH; lutropin) and human choriogonadotropin (hCG) is crucial for normal sexual development and fertility. We aimed to unravel differences between the two hLHR hormones in molecular activation mechanisms at hLHR. We utilized a specific hLHR variant that lacks exon 10 (hLHR-delExon10), which maintains full cAMP signaling by hCG, but decreases hLH-induced receptor signaling, resulting in a pathogenic phenotype. Exon 10 encodes 27 amino acids within the hinge region, which is an extracellular segment that is important for signaling and hormone interaction. Initially, we assumed that the lack of exon 10 might disturb intermolecular trans-activation of hLH, a mechanism that has been reported for hCG at hLHR. Coexpression of signaling-deficient hLHR and binding-deficient hLHR can be used to examine the mechanisms of receptor signaling, in particular intermolecular cooperation and intramolecular cis-activation. Therefore, hLHR-delExon10 was combined with the hLHR Lys605→Glu mutant, in which signaling is abolished, and the hLHR mutant Cys131→Arg, in which binding is deficient. We found that hCG signaling was partially rescued, indicating trans-activation. However, the hLH signal could not be restored via forced trans-activation with any construct. Fluorescence cross-correlation spectroscopy detected oligomerization in all combinations, indicating that these functional differences cannot be explained by monomerization of hLHR-delExon10. Thus, our data demonstrate not only that the different behavior of hLH at hLHR-delExon10 is unlikely to be related to modified intermolecular receptor activation, but also that hLH may exclusively stimulate the targeted hLHR by cis-activation, whereas hCG is also capable of inducing trans-activation.
Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Paul
P
Grzesik
Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Anke
A
Teichmann
Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Jens
J
Furkert
Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Claudia
C
Rutz
Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Burkhard
B
Wiesner
Institute of Experimental Pediatric Endocrinology, Charité-Universitätsmedizin Berlin, Germany.
Gunnar
G
Kleinau
Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Ralf
R
Schülein
Center of Reproductive Medicine and Andrology, University Clinics, Münster, Germany.
Jörg
J
Gromoll
Leibniz-Institut für Molekulare Pharmakologie (FMP), Berlin, Germany.
Gerd
G
Krause
D019943:Amino Acid Substitution; D002462:Cell Membrane / Q000378:metabolism; D006063:Chorionic Gonadotropin / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism; D005091:Exons; D057809:HEK293 Cells; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism*; D016297:Mutagenesis, Site-Directed; D050505:Mutant Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D020836:Protein Structure, Quaternary; D011974:Receptors, LH / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D017384:Sequence Deletion; D015398:Signal Transduction; D015533:Transcriptional Activation
D006063:Chorionic Gonadotropin; D050505:Mutant Proteins; D011974:Receptors, LH; D007986:Luteinizing Hormone; D000242:Cyclic AMP
G-protein-coupled receptors; activation mechanism; glycoprotein hormone receptors; lutropin receptor; oligomerization